S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Options trading has suddenly become more reliable. (Ad)
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
The #1 Crypto for 2024 (Ad)
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Options trading has suddenly become more reliable. (Ad)
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
The #1 Crypto for 2024 (Ad)
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Options trading has suddenly become more reliable. (Ad)
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
The #1 Crypto for 2024 (Ad)
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Options trading has suddenly become more reliable. (Ad)
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
The #1 Crypto for 2024 (Ad)
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
Free Trial
NASDAQ:FSTX

F-star Therapeutics (FSTX) Stock Price, News & Analysis

→ Forget Nvidia, buy this A.I. Stock Now (From InvestorPlace) (Ad)
Free FSTX Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$7.12
▼
$7.12
50-Day Range
$4.42
▼
$7.12
52-Week Range
$2.07
▼
$7.12
Volume
N/A
Average Volume
709,213 shs
Market Capitalization
$156.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
FSTX stock logo

About F-star Therapeutics Stock (NASDAQ:FSTX)

F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.

FSTX Stock News Headlines

July 20, 2023 | dailymail.co.uk
Adam22's porn star wife Lena The Plug ADMITS she enjoyed sex with other man MORE than husband's
July 12, 2023 | finance.yahoo.com
A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US
April 17, 2024 | InvestorPlace (Ad)
Forget Nvidia, buy this A.I. Stock Now
Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.
July 11, 2023 | dailymail.co.uk
Twitch star Amouranth reveals she has been diagnosed with 'late stage ovarian failure' at AGE 29 - after 'shrugging off confusing mental and physical symptoms' for MONTHS
June 26, 2023 | startribune.com
Douglas F. Mayo
June 2, 2023 | finance.yahoo.com
Ochre Bio Appoints Eliot Forster, Ph.D. as Chairperson of its Board of Directors
April 24, 2023 | sfgate.com
F. Murray Abraham apologizes after sexual misconduct allegations
March 8, 2023 | businesswire.com
invoX Pharma Completes Acquisition of F-star Therapeutics, Inc.
April 17, 2024 | InvestorPlace (Ad)
Forget Nvidia, buy this A.I. Stock Now
Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.
March 7, 2023 | finanznachrichten.de
F-star Therapeutics, Inc.: F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma
March 7, 2023 | msn.com
F-star Therapeutics surges as buyer Sino Biopharma gains CFIUS approval
March 7, 2023 | marketwatch.com
F-star Therapeutics Shares Rally After Cfius Clears Takeover >FSTX
March 7, 2023 | msn.com
Why F-Star Therapeutics Shares Are Moving Higher
March 7, 2023 | finance.yahoo.com
F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma
March 7, 2023 | msn.com
F-Star Therapeutics Blasts Up as Merger Deal Goes Through
March 7, 2023 | finance.yahoo.com
F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma
March 7, 2023 | msn.com
F-star Therapeutics surges on report sale to Sino Biopharma close to CFIUS approval
February 25, 2023 | seekingalpha.com
F-star Therapeutics jumps as it extends walk date with buyer to `finalize' CFIUS agreement
February 25, 2023 | morningstar.com
F-star Therapeutics Inc Ordinary Shares
February 23, 2023 | msn.com
F-star Therapeutics jumps as it extends walk date with buyer to `finalize" CFIUS agreement
February 22, 2023 | finance.yahoo.com
While institutions own 48% of F-star Therapeutics, Inc. (NASDAQ:FSTX), retail investors are its largest shareholders with 49% ownership
February 9, 2023 | msn.com
F-star Therapeutics gains after deal termination date with buyer extended again
February 8, 2023 | msn.com
F-star Therapeutics gains as buyer Sino Biopharma cancels Shanghai listing
February 1, 2023 | msn.com
F-star Therapeutics up 18% as it extends end date of merger with invoX Pharma
January 26, 2023 | finanznachrichten.de
F-star Therapeutics, Inc.: invoX Pharma and F-star Therapeutics issue Joint Statement
January 26, 2023 | seekingalpha.com
FSTX F-star Therapeutics, Inc.
January 26, 2023 | msn.com
F-star Therapeutics partly pares loss as buyer says in active talks with CFIUS (update)
See More Headlines
Receive FSTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for F-star Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/17/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FSTX
CUSIP
N/A
CIK
1566373
Web
www.f-star.com
Phone
441223497400
Fax
508-381-0347
Employees
84
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.82)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-31,280,000.00
Net Margins
N/A
Pretax Margin
-213.97%
Return on Equity
-57.08%
Return on Assets
-42.40%

Debt

Debt-to-Equity Ratio
0.15
Current Ratio
3.38
Quick Ratio
3.38

Sales & Book Value

Annual Sales
$21.17 million
Price / Sales
7.39
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.70 per share
Price / Book
1.51

Miscellaneous

Outstanding Shares
21,980,000
Free Float
21,279,000
Market Cap
$156.50 million
Optionable
Not Optionable
Beta
0.85
10 Best Cheap Stocks to Buy Now Cover
10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Eliot Richard Forster
    President, Chief Executive Officer & Director
  • Darlene M. Deptula-Hicks
    Chief Financial Officer, Treasurer & Secretary
  • Louis KayitalireLouis Kayitalire
    Chief Medical Officer
  • Neil Brewis
    Chief Scientific Officer
  • James Sandy
    Chief Development Officer

Key Competitors

View All Competitors

FSTX Stock Analysis - Frequently Asked Questions

How were F-star Therapeutics' earnings last quarter?

F-star Therapeutics, Inc. (NASDAQ:FSTX) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.06. The company earned $0.75 million during the quarter, compared to the consensus estimate of $7.18 million.

This page (NASDAQ:FSTX) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
He Is Giving Away Bitcoin
Crypto Swap Profits
Options trading has suddenly become more reliable.
Eagle Publishing
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
Top 5 Tech Stocks to Buy for 2024
Daily Market Alerts
The #1 Crypto for 2024
InvestorPlace
The Greatest Bull Market in Crypto History…
Weiss Ratings
A.I. is a Tidal Wave - Here’s What to Buy
Chaikin Analytics